Aprea Therapeutics, Inc. — Form 8-K Summary
Business context and reporting period
Aprea Therapeutics, Inc. filed a Form 8-K dated October 13, 2021, under Item 5.02. The company is a Delaware corporation headquartered in Boston, Massachusetts, with common stock trading on the Nasdaq Global Select Market under the symbol APRE.
Material corporate change
- Johan Christenson, M.D., Ph.D. resigned from Aprea’s Board of Directors.
- The resignation was effective upon the filing of the company’s Form 10-Q for the third quarter of 2021.
- The company stated that the resignation did not result from any disagreement regarding operations, policies, or practices.
Financial metrics, liquidity, and outlook
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, guidance, or other operating-performance metrics. It also does not provide a financial outlook or new risk disclosures.
Investor verification points
- Verify the effective date of the director’s resignation against the company’s third-quarter 2021 Form 10-Q filing.
- Review subsequent filings for changes to the Board of Directors or committee composition.
- Consult the third-quarter 2021 Form 10-Q for the company’s financial condition, liquidity, operating results, and risk factors, which are not addressed in this Form 8-K.